Cingulate Inc (CING) Stock Price, Quote & News

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1...

Industry: Biotechnology

Sector: Healthcare

Phone: 913 942 2300

Website: www.cingulate.com

Address:

1901 West 47th Place, Kansas City, United States

hawkmdend Oct. 3 at 3:43 PM

$CING I have to add $COLL as a potential buyer/partner. The new Chief Legal Officer, Nilay Patel, comes from Ironshore Pharm, which Collegium acquired to expand its presence in the ADHD/CNS space. This is getting very interesting… my Money is with COLL or $SUPN. I'm done with my DD. Happy trading, nothing else to add.

1 · Reply

hawkmdend Oct. 3 at 2:52 PM

$CING IMO, Cingulate is for sale. The latest moves by Bod/executives are telling the story. COO out, Expert in deals hired-CLO( check Ironshore Pharm-Buyout), problematic CEO out, Interim CFO-CEO. The ADHD market is too lucrative for current players in the CNS space to let a new player capture a significant portion of their market share. Who in the CNS space could be the buyer? I will go with $SUPN, Otsuka, or maybe a division of JNJ. Anyone with other potential players?

2 · Reply

fullobullz Oct. 3 at 12:21 PM

$CING So even after the 60-day filing review, it still takes up to an additional 14 days for FDA to notify the company of the review timeline and PDUFA date. Wouldnt expect any announcement until dates and review process have be finalized guys.

1 · Reply

Duke1979 Oct. 3 at 11:14 AM

$CING if you look at the timing of the press release for the submission it was 6 days after they filled for the NDA. So same logic used if it took the full 60 days for approval, we are looking at a Tuesday or Wednesday of next week for news. Just buy while you can at this point IMO. Enjoy your weekend and it sounds cliche’, but know what you hold.

0 · Reply

HouseOfTheDragons Oct. 3 at 2:36 AM

Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $CELZ $CING $CISO $CRKN R

0 · Reply

pitkineagle Oct. 2 at 10:38 PM

$CING Gee, they should know by now 😏

0 · Reply

Duke1979 Oct. 2 at 6:50 PM

$CING MM controlling the price. Just relax everyone. The time is drawing near.

0 · Reply

DonkeyClanbrands Oct. 2 at 6:19 PM

$CING highly recommend looking at $ASST AND $GANX

1 · Reply

PhiloftheFuture Oct. 2 at 5:45 PM

$CING opened a position here today

1 · Reply

sam9420 Oct. 2 at 4:23 PM

$CING why we can't keep that above 4.30 $?!

1 · Reply

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Aug 21, 2025, 4:35 PM EDT - 6 weeks ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 19, 2025, 8:45 AM EDT - 6 weeks ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 15, 2025, 9:00 AM EDT - 7 weeks ago

Cingulate Provides Management Team Update

Aug 6, 2025, 8:45 AM EDT - 2 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Jun 18, 2025, 8:00 AM EDT - 3 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

May 8, 2025, 4:30 PM EDT - 5 months ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Apr 9, 2025, 8:00 AM EDT - 6 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Mar 26, 2025, 5:00 PM EDT - 6 months ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Dec 23, 2024, 7:30 AM EST - 10 months ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Nov 7, 2024, 7:30 AM EST - 11 months ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

May 8, 2024, 7:00 AM EDT - 1 year ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Apr 30, 2024, 5:45 AM EDT - 1 year ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 16, 2024, 5:00 PM EDT - 1 year ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Mar 6, 2024, 6:45 AM EST - 1 year ago

Cingulate to Attend DCAT Week 2024 in New York City

Feb 13, 2024, 6:45 AM EST - 1 year ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 6, 2024, 4:15 PM EST - 1 year ago

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 1 year ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Jan 29, 2024, 8:00 AM EST - 1 year ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 6:45 AM EST - 1 year ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Dec 28, 2023, 7:19 AM EST - 1 year ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Jun 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 14, 2023, 3:45 PM EDT - 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

May 25, 2023, 3:55 PM EDT - 2 years ago

Cingulate to Present at 13th Annual LD Micro Invitational

May 12, 2023, 3:45 PM EDT - 2 years ago

Cingulate, Indegene to Participate in Benzinga All Live Access Event

May 10, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

hawkmdend Oct. 3 at 3:43 PM

1 · Reply

hawkmdend Oct. 3 at 2:52 PM

2 · Reply

fullobullz Oct. 3 at 12:21 PM

1 · Reply

Duke1979 Oct. 3 at 11:14 AM

0 · Reply

HouseOfTheDragons Oct. 3 at 2:36 AM

0 · Reply

pitkineagle Oct. 2 at 10:38 PM

$CING Gee, they should know by now 😏

0 · Reply

Duke1979 Oct. 2 at 6:50 PM

$CING MM controlling the price. Just relax everyone. The time is drawing near.

0 · Reply

DonkeyClanbrands Oct. 2 at 6:19 PM

$CING highly recommend looking at $ASST AND $GANX

1 · Reply

PhiloftheFuture Oct. 2 at 5:45 PM

$CING opened a position here today

1 · Reply

sam9420 Oct. 2 at 4:23 PM

$CING why we can't keep that above 4.30 $?!

1 · Reply

JuanDonde10 Oct. 2 at 4:01 PM

$CING I’m close to going all in seems pretty de-risked since the last hurdle is the FDA approval hmmm…

0 · Reply

lordofthesox Oct. 2 at 3:57 PM

$CING I see a lot of posts here with people seeming to suggest that a potential NDA approval is almost synonymous with the drug being approved. My understanding is that NDA approval just means the FDA confirms that they submitted all the necessary paperwork and they'll take another 6-10 months to review it and make an approval decision, which doesn't seem like that big of a catalyst for the stock/company. Am I missing something?

3 · Reply

hawkmdend Oct. 2 at 1:37 PM

$CING Now that we have passed that window (a bullish sign for the market), I'm wondering if the current silence is due to a potential deal being finalized. I hope they sell now for 300-500M and let the big boys handle the commercial launch.

2 · Reply

JacobJones1 Oct. 2 at 12:24 PM

$CING continues to inch up.

0 · Reply

ibaian Oct. 2 at 11:32 AM

$CING IBISWorld projects that drugmaker revenue from ADHD medications will rise 13% this year, reaching $12.9 billion. In addition, such revenue is expected to grown at an annualized rate of 6.3% and reach $17.5 billion over the next five years.

0 · Reply

ibaian Oct. 2 at 11:18 AM

$CING In the U.S., over 20 million patients have been diagnosed with ADHD. Among this group, 12 million are adults and over 8 million are under the age of 17. According to the CDC, just 53.6 percent of all children and teens with ADHD reported they were actively treating their symptoms with medication in 2022, with 65-90 percent demonstrating clinical ADHD symptoms that persist into adulthood. Current market trends demonstrate that adult ADHD prevalence is larger and growing faster than the child and adolescent segments combined.

0 · Reply

ibaian Oct. 2 at 11:16 AM

$CING If approved, CTx-1301 would become a potential first-line treatment for ADHD,

0 · Reply

Sam898989 Oct. 2 at 4:17 AM

$CING The 60-day “filing review” window is an FDA’s internal deadline to decide whether the submission is complete and “filed” (i.e. accepted for full review). But public announcements often lag — firms may wait until they have formal word, manage internal review, approve press materials, or coordinate investor communication. Thus, seeing no public announcement exactly on Day 60 is not unusual, especially for smaller or mid-size biotech companies that may have to reconcile internal and legal checks before going public.

0 · Reply

catalysthunter Oct. 2 at 2:27 AM

$CING Guys, approval date for nda applications seems to be imminent. They may have already received application completion and are waiting to release the announcement. But the concern is that the stock price falls even after the news comes out. We already remember that the stock price fell by 5-10% not long ago even after hearing the partnership news and the news of nda application completion. In addition, when looking at this year's nda application approval cases of small pharmaceutical companies,(GRCE and ARHV), even after the nda applications and pdufa, there seems to be a great tendency to fall and after a short period of rise by around 10%. How do you think the stock price will move objectively without a hype

1 · Reply

Sam898989 Oct. 2 at 12:01 AM

$CING The Wednesday Weekly USA patent update. Change or no change, every Wednesday, will be positing it: Here’s the updated status for Application US 18/661,378 (Tripulse Release Stimulant Formulations), as of October 1, 2025: ________________________________________ Application US18/661,378 (Tripulse Release Stimulant Formulations) • 2024-05-10 – Application filed by Cingulate Therapeutics LLC • 2024-05-10 – Priority date established (same day as filing) • 2024-11-11 – Assignment recorded to Cingulate Therapeutics LLC (Reel/Frame 069201/0426) • 2025-02-13 – Publication of application as US 2025/0049722 A1 • 2025-10-01 (today) – Status: Pending (no Office Action issued yet; still early in prosecution) ________________________________________ Notes • The application is still in the early prosecution phase. • No examiner assignment posted since publication. •Based on USPTO averages for pharma/chemical filings, the First Office Action is expected between late-2025 and early-2026.

0 · Reply

hawkmdend Oct. 1 at 8:06 PM

$CING As expected. Tomorrow should be another mini higher move, unless we receive the NDA news with an update.

0 · Reply

user0987134 Oct. 1 at 7:46 PM

$CING $IXHL hi fuck off

0 · Reply

Market Cap	22.62M
Revenue (ttm)	0.00
Net Income (ttm)	-15.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	131,600
Avg Vol	151,140
Day's Range	N/A - N/A
Shares Out	5.41M
Stochastic %K	87%
Beta	-0.75
Analysts	Strong Sell
Price Target	$29.00